Inversago Pharma Receives $7M in Series A Financing

Inversago Pharma, Inc., a Montreal, Canada-based preclinical-stage biotech company, secured a $7m Series A financing.

The round was co-led by Genesys Capital and Amorchem, with participation from the JDRF T1D Fund, Accel-Rx, Anges Québec Capital, Anges Québec, Tarnagulla Ventures and angel investors.

The company intends to use the funds to advance its peripherally-restricted CB1 inverse agonist/antagonist program into clinical trials.

Led by François Ravenelle, Chief Executive Officer and Founder, Inversago develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome (PWS), type 1 diabetes (T1D), obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH).
The company’s technology, based on the work by CB1 world expert George Kunos at the National Institute of Health (NIH/NIAAA), has demonstrated that in preclinical models, peripherally restricted CB1 blockade provides a clear therapeutic potential to treat conditions like obesity, NASH, liver fibrosis and diabetes, without causing the CNS or behavioural effects associated with the earlier generations of CB1 blockers.



Join the discussion